LLY

763.7

-0.64%↓

JNJ

177.13

+0.26%↑

ABBV

220.14

+1.49%↑

UNH

340.38

-0.31%↓

AZN

77.7

-0.31%↓

LLY

763.7

-0.64%↓

JNJ

177.13

+0.26%↑

ABBV

220.14

+1.49%↑

UNH

340.38

-0.31%↓

AZN

77.7

-0.31%↓

LLY

763.7

-0.64%↓

JNJ

177.13

+0.26%↑

ABBV

220.14

+1.49%↑

UNH

340.38

-0.31%↓

AZN

77.7

-0.31%↓

LLY

763.7

-0.64%↓

JNJ

177.13

+0.26%↑

ABBV

220.14

+1.49%↑

UNH

340.38

-0.31%↓

AZN

77.7

-0.31%↓

LLY

763.7

-0.64%↓

JNJ

177.13

+0.26%↑

ABBV

220.14

+1.49%↑

UNH

340.38

-0.31%↓

AZN

77.7

-0.31%↓

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Open

1.48 -3.27

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.46

Max

1.53

Schlüsselkennzahlen
By Trading Economics
Einkommen	13M -43M
Gewinnspanne	-2,190.837
Angestellte	171
EBITDA	17M -42M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+75.16% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	6. Nov. 2025

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1.8M 106M
Vorheriger Eröffnungskurs	4.75
Vorheriger Schlusskurs	1.48

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Sept. 2025, 17:03 UTC

Wichtige Markttreiber

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16. Sept. 2025, 16:49 UTC

Wichtige Markttreiber

Akquisitionen, Fusionen, Übernahmen

GD Culture Shares Drop After Deal for Pallas Capital

16. Sept. 2025, 16:11 UTC

Wichtige Markttreiber

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16. Sept. 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16. Sept. 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16. Sept. 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16. Sept. 2025, 21:10 UTC

Akquisitionen, Fusionen, Übernahmen

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16. Sept. 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16. Sept. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16. Sept. 2025, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

16. Sept. 2025, 20:25 UTC

Ergebnisse

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16. Sept. 2025, 20:24 UTC

Ergebnisse

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16. Sept. 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16. Sept. 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16. Sept. 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16. Sept. 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16. Sept. 2025, 18:40 UTC

Akquisitionen, Fusionen, Übernahmen

Details Emerge on U.S.-China TikTok Deal -- WSJ

16. Sept. 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16. Sept. 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16. Sept. 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16. Sept. 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16. Sept. 2025, 16:53 UTC

Ergebnisse

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16. Sept. 2025, 16:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

16. Sept. 2025, 16:15 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Global Commodities Roundup: Market Talk

16. Sept. 2025, 16:09 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Global Energy Roundup: Market Talk

16. Sept. 2025, 16:09 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16. Sept. 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. Sept. 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16. Sept. 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16. Sept. 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

75.16% Vorteil

12-Monats-Prognose

Durchschnitt 2.68 USD 75.16%

Hoch 4 USD

Tief 1.7 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.